Searched for
NOVO NORDISK TAKEOVER
US Stocks | Wall Street ends sharply lower amid AI displacement fears and revived tariff angstA broad selloff sent all three major U.S. stock indexes more than 1% lower by the closing bell, as risk appetite was dampened by a combinat...- S&P 500, Dow Jones, Nasdaq crash at U.S Stock Market. Top gaining, losing stocks at Wall StreetU.S Stock Market today: On Wall Street, big losses hit companies under suspicion of getting undercut by AI-powered rivals. Investors have b...
- Market Wrap: Sensex adds 485 points, Nifty extends gain for second session to end above 25,850; smallcap index rockets 2.65%Benchmark indices Nifty and Sensex kicked off the week on a strong footing, extending gains for a second straight session on Monday. The ra...
- Metsera accepts Pfizer's $10 billion bid in ongoing M&A battleMetsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per sh...
- Pfizer weighs sweeter offer for Metsera after Judge blocks bid to halt Novo Nordisk’s $10 billion takeoverPfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's bid. Pfizer's d...
- European stocks set to wipe out weekly gains as banks plungeEuropean shares tumbled on Friday, on course for their biggest drop in six weeks, as renewed concerns about the health of U.S. regional ban...
- Novo, CPPIB, Permira among others circle Tata 1mg for $200 million booster shotInvestors baulk at $1.2 billion valuation, some seek board seat, part funding from Tatas. If the valuation deadlock persists, Tata Sons may...
- Tata 1mg likely to get $200 mn booster shot; Novo, CPPIB, Permira and ChrysCap line upNovo Holdings, CPPIB, Permira, and ChrysCapital have shown interest in investing in Tata Group’s online pharmacy 1mg, which seeks up to $20...
- Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera: ReportPfizer is close to acquiring Metsera, an anti-obesity drug developer. The deal could be worth $7.3 billion. Pfizer will pay $47.50 per shar...
- US stock market today: Nasdaq jumps, S&P 500 nears record, and Dow climbs — Nvidia surges as Fed cut hopes Middle East truceUS Stock market today saw the Nasdaq leading a tech-powered rally, while the S&P 500 moved closer to record highs, thanks to investor optim...
- AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolioAstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims ...
- AstraZeneca targets 2024 growth but mixed views hit sharesIn almost a decade since AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot has rebuilt the Anglo-Swedish drugmaker'...
- Dr Reddy’s Laboratories founder Anji Reddy passes awayAnji Reddy, the pharmaceutical industry pioneer who helped establish India’s reputation as a supplier of inexpensive medicines to the world...
Load More
